Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias

Psychopharmacology
Spiridon KonitsiotisAngelos Evangelou

Abstract

Tardive dyskinesia is a syndrome of abnormal, involuntary movements, which occurs as a complication of long-term neuroleptic therapy. The pathophysiology of this potentially irreversible syndrome is still an enigma. The objective of the present study was to elucidate the role of N-methyl-D-aspartate (NMDA) receptor involvement in neuroleptic-induced orofacial dyskinesia in rats. Animals chronically treated with haloperidol for a period of 40 weeks exhibited significantly more vacuous chewing movements (VCMs), as compared to vehicle-treated controls. In a series of acute experiments, rats received: amantadine (10, 20, and 40 mg/kg i.p.), a low-affinity, uncompetitive NMDA-receptor antagonist (open channel blocker); dextrorphan (5, 10, and 20 mg/kg i.p.), an NMDA receptor channel antagonist; ifenprodil (2.5, 5, and 10 mg/kg i.p.), a noncompetitive allosteric NMDA receptor antagonist acting at the polyamine site; and Ro 25-6981 (2.5, 5, and 10 mg/kg i.p.), a potent and selective blocker of NMDA receptors which contain the NR2B subunit. All the drugs tested, except dextrorphan, reduced VCMs and tongue protrusions with varying efficacies and side effects profiles. Ro 25-6981 was found significantly more potent than amantadine and if...Continue Reading

References

Jul 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·J L MontastrucA Rascol
Jan 1, 1994·European Journal of Pharmacology·K HashimotoE D London
Oct 1, 1993·Clinical Neuropharmacology·B Gomez-Mancilla, P J Bédard
Sep 1, 1996·Movement Disorders : Official Journal of the Movement Disorder Society·P J BlanchetT N Chase
Jun 5, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·L Verhagen MetmanT N Chase
Nov 11, 1999·Archives of Neurology·L V MetmanT N Chase
Jan 14, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·L V MetmanT N Chase
Apr 1, 1997·Journal of Clinical Psychopharmacology·S AngusN M Schneider
Jun 16, 2001·European Journal of Pharmacology·P S Naidu, S K Kulkarni

❮ Previous
Next ❯

Citations

Jul 27, 2012·Translational Psychiatry·S A IvanovaB Wilffert
Dec 3, 2010·Clinical Neuropharmacology·Sofia PappaSpiridon Konitsiotis
Mar 3, 2011·Journal of Clinical Psychopharmacology·Yesim Yetimalar BeckmannYeliz Çiftçi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here